Long-term outcomes with intensive induction chemotherapy (carboplatin, bleomycin, vincristine and cisplatin/bleomycin, etoposide and cisplatin) and standard bleomycin, etoposide and cisplatin in poor prognosis germ cell tumours: A randomised phase II trial (ISRCTN53643604).

•Intensive induction chemotherapy met response targets in poor prognosis germ cell tumours.•Three-year progression-free survival was 56% for CBOP/BEP and 39% for BEP.•Impact on survival was less clear and will be affected by subsequent therapy.•Further study in an international phase III trial is warranted.